Summary
Gilead Sciences, Inc. reported strong revenue growth in the third quarter of 2024, with total revenues reaching $7.5 billion, a 7% increase year-over-year, driven primarily by robust performance in its HIV segment. This growth was partially offset by significant non-cash charges, including an $1.8 billion impairment related to the Trodelvy NSCLC IPR&D asset and higher acquired IPR&D expenses, which resulted in a net loss of $1.3 billion for the nine-month period. Despite the net loss, the company demonstrated positive operating cash flow, highlighting the underlying strength of its commercial operations and the ongoing demand for its key products. The company continues to strategically invest in its pipeline and expand its portfolio through acquisitions and collaborations. Notable developments include the FDA's accelerated approval of Livdelzi for primary biliary cholangitis and positive Phase 3 data for lenacapavir in HIV prevention, positioning Gilead for future growth. However, the company faces ongoing legal challenges and potential patent expirations, which remain key areas for investor attention.
Financial Highlights
55 data points| Revenue | $7.54B |
| Cost of Revenue | $1.57B |
| Gross Profit | $5.97B |
| SG&A Expenses | $1.43B |
| Operating Expenses | $6.66B |
| Operating Income | $888.00M |
| Net Income | $1.25B |
| EPS (Basic) | $1.00 |
| EPS (Diluted) | $1.00 |
| Shares Outstanding (Basic) | 1.25B |
| Shares Outstanding (Diluted) | 1.25B |
Key Highlights
- 1Total revenues increased 7% to $7.5 billion for the three months ended September 30, 2024, and 6% to $21.2 billion for the nine months ended September 30, 2024.
- 2HIV product sales showed significant strength, increasing by 9% to $5.1 billion for the third quarter and 5% to $14.2 billion year-to-date.
- 3A substantial $1.8 billion in-process research and development (IPR&D) impairment charge was recorded in the third quarter related to the Trodelvy NSCLC asset, and a total of $4.2 billion for the nine-month period.
- 4The company completed the acquisition of CymaBay Therapeutics for $3.9 billion net cash consideration, adding seladelpar to its liver disease portfolio.
- 5FDA granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis.
- 6Net cash provided by operating activities for the nine months ended September 30, 2024, was $7.9 billion.
- 7The company announced plans to voluntarily withdraw the U.S. accelerated approval of Trodelvy for a specific urothelial cancer indication.